Decode the Immunoscience of age-related diseases

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new data-driven research by building AI infrastructure on existing data and cohorts that no single organisation could develop independently Patients and citizens will benefit from improved medical practice and healthcare solutions, new targeted prevention strategies and ultimately healthier ageing. The action will support EU policy and priorities including the European Health Data Space Regulation (EHDS) and the EU Artificial Intelligence Act, while contributing to European competitiveness in addressing one of society's major challenges. Expected Outcome: The action under this topic must contribute to all of the following outcomes: Researchers will benefit from a better understanding of the potential causal links between chronic inflammatory diseases and biological ageing , and the predictiveness of the accompanying biomarkers could allow for the definition of precise risk profiles for age-associated immune disease onset and exacerbations. Patients will benefit from new early detection strategies as well as new diagnostic approaches to differentiate disease onset in elderly people from onset in younger adults . This will inform a personalised medicine approach to treatment and will in turn help to prevent disease progression. Patients and healthcare professionals will benefit from the repurposing or development of novel therapies for ageing populations with chronic inflammatory disea…